Fig 1: NKG2DHigh CD8 T cells are more activated than NKG2DLowcells are. (a) A representative histogram showing NKG2D expression before (left) and after (right) sorting. (b) IFNG mRNA expression of NKG2DHigh or NKG2DLow CD8 T cells cocultured with PANC-1 cells for 72 h. Data are represented as fold-changes relative to the NKG2DHigh T cells and are means with S.E.M. from four experiments using T cells from two different donors. Each pair of connected dots represents data from a single experiment. (c) Expression of surface activation markers of NKG2DHigh or NKG2DLow CD8 T cells cocultured with PANC-1 cells. Data are mean with SEM from four independent experiments using T cells from three different donors. Each pair of connected dots represents data from a single experiment.
Fig 2: CD19/NKG2DL tandem CAR design. Schematic representation of single and tandem CAR constructs. scFv FMC63, single-chain variable fragment anti-CD19; NKG2D EC, extracellular domain of human NKG2D; (G4S)3, Glycine-Serine linker; CD8α H55, 55 amino acids hinge from human CD8α; CD8α H12, 12 amino acids hinge from human CD8α; IgG4 H12, 12 amino acids hinge from human IgG4; CD8α TM, transmembrane region from human CD8α; 4-1BB, intracellular domain from 4-1BB; CD3ζ, intracellular domain from human CD3ζ; 2A, 2A self-cleaving peptide; tCD34, truncated CD34; shRNAMICA/B-CD3ζ, shRNA duplex targeting MICA/B and CD3ζ.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human NKG2D Fc Chimera Protein, CF